CAN-2409 is an immunotherapy drug currently in a Phase 3 clinical trial (PrTK03, NCT01436968) for individuals with intermediate-high risk localized prostate cancer.
The trial, which is expected to conclude in December 2024, is evaluating the effectiveness of CAN-2409 in combination with radiation therapy. This placebo-controlled study involves 711 participants from the US and Puerto Rico who undergo monitoring every six months for a duration of five years.
The primary objective of the trial is to determine disease-free survival rates. CAN-2409 functions by utilizing an inactivated herpes virus as a vehicle to transport a specific gene directly into cancer cells. Subsequent administration of Valtrex (valacyclovir), an anti-herpetic medication, aims to eliminate the cells containing the introduced gene.
ONCOLYTIC VIRUSES ARE ON THE MOVE!
Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy
Developments in the Continued Search for a Prostate Cancer Vaccine...
BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival